NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Price & Overview
OSL:NYKD • NO0010714785
Current stock price
The current stock price of NYKD.OL is 2.966 NOK. Today NYKD.OL is down by -3.83%. In the past month the price increased by 2.49%. In the past year, price increased by 29.63%.
NYKD.OL Key Statistics
- Market Cap
- 968.547M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.36
- Dividend Yield
- 32.43%
NYKD.OL Stock Performance
NYKD.OL Stock Chart
NYKD.OL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL is one of the better performing stocks in the market, outperforming 85.85% of all stocks.
NYKD.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. The financial health of NYKD.OL is average, but there are quite some concerns on its profitability.
NYKD.OL Earnings
NYKD.OL Forecast & Estimates
7 analysts have analysed NYKD.OL and the average price target is 4.59 NOK. This implies a price increase of 54.75% is expected in the next year compared to the current price of 2.966.
For the next year, analysts expect an EPS growth of -114.29% and a revenue growth -100% for NYKD.OL
NYKD.OL Groups
Sector & Classification
NYKD.OL Financial Highlights
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 68.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.25% | ||
| ROE | -13.37% | ||
| Debt/Equity | 0.01 |
NYKD.OL Ownership
NYKD.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.07 | 37.588B | ||
| 1AE | ARGENX SE | 25.06 | 37.563B | ||
| 22UA | BIONTECH SE-ADR | N/A | 17.926B | ||
| ABVX | ABIVAX SA | N/A | 7.053B | ||
| 2X1 | ABIVAX SA | N/A | 7.037B | ||
| GXE | GALAPAGOS NV | N/A | 1.675B | ||
| GLPG | GALAPAGOS NV | N/A | 1.671B | ||
| NANO | NANOBIOTIX | N/A | 1.282B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.038B | ||
| PHIL | PHILOGEN SPA | 18.09 | 660.824M | ||
| GNFT | GENFIT | 815.2 | 415.774M | ||
| FYB | FORMYCON AG | N/A | 312.052M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NYKD.OL
Company Profile
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 59 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Company Info
IPO: 2020-01-27
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 75
Phone: 4722958193
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What does NYKODE THERAPEUTICS ASA do?
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 59 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
What is the stock price of NYKODE THERAPEUTICS ASA today?
The current stock price of NYKD.OL is 2.966 NOK. The price decreased by -3.83% in the last trading session.
Does NYKD stock pay dividends?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 32.43%. The yearly dividend amount is currently 0.96.
What is the ChartMill rating of NYKODE THERAPEUTICS ASA stock?
NYKD.OL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is NYKODE THERAPEUTICS ASA (NYKD.OL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NYKD.OL.
What is NYKODE THERAPEUTICS ASA worth?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 968.55M NOK. This makes NYKD.OL a Small Cap stock.
What is the ownership structure of NYKODE THERAPEUTICS ASA (NYKD.OL)?
You can find the ownership structure of NYKODE THERAPEUTICS ASA (NYKD.OL) on the Ownership tab.